Advertisement

Primary Central Nervous System Lymphoma

  • Oussama AblaEmail author
  • Tracy T. Batchelor
  • Andishe Attarbaschi
Chapter

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare brain tumor in childhood. The exact incidence and pathogenesis in children are unknown. Due to the rarity and absence of prospective clinical trials, therapeutic decisions are usually derived from pediatric case series and adult trials. Most patients have favorable outcomes after treatment with regimens that include high-dose methotrexate and high-dose cytarabine. The role of rituximab and intrathecal chemotherapy is not well established, while whole-brain radiotherapy is routinely reserved for refractory or relapsed disease. A better understanding of the molecular biology of pediatric PCNSL and an ongoing international case registry might provide better insights and outcomes for this rare pediatric lymphoma subtype.

Keywords

CNS lymphoma Children Primary Adolescents Treatment 

References

  1. 1.
    Batchelor TT, DeAngelis LM, editors. Lymphoma and leukemia of the nervous system. 2nd ed. New York: Springer; 2013.Google Scholar
  2. 2.
    Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-Oncology. 2014;16(Suppl 4):iv1–63.CrossRefGoogle Scholar
  3. 3.
    Abla O, Weitzman S, Blay JY, O’Neill BP, Abrey LE, Neuwelt E, et al. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). Clin Cancer Res. 2011;17(2):346–52.CrossRefGoogle Scholar
  4. 4.
    Hochberg J, El-Mallawany NK, Abla O. Adolescent and young adult non-Hodgkin lymphoma. Br J Haematol. 2016;173(4):637–50.CrossRefGoogle Scholar
  5. 5.
    Matinella A, Lanzafame M, Bonometti MA, Gajofatto A, Concia E, Vento S, et al. Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study. J Neurol. 2015;262(5):1317–27.CrossRefGoogle Scholar
  6. 6.
    Cavaliere R, Petroni G, Lopes MB, Schiff D, International Primary Central Nervous System Lymphoma Collaborative Group. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Cancer. 2010;116(4):863–70.CrossRefGoogle Scholar
  7. 7.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.Google Scholar
  8. 8.
    Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190–6.CrossRefGoogle Scholar
  9. 9.
    Ponzoni M, Issa S, Batchelor TT, Rubenstein JL. Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol. 2014;25(2):316–22.CrossRefGoogle Scholar
  10. 10.
    Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–81.CrossRefGoogle Scholar
  11. 11.
    Abla O, Sandlund JT, Sung L, et al. A case series of pediatric primary central nervous system lymphoma: favorable outcome without cranial irradiation. Pediatr Blood Cancer. 2006;47:880–5.CrossRefGoogle Scholar
  12. 12.
    Abla O, Weitzman S. Primary CNS lymphoma in children. Neurosurg Focus. 2006;21:E8.CrossRefGoogle Scholar
  13. 13.
    Thorer H, Zimmermann M, Makarova O, et al. Primary central nervous system lymphoma in children and adolescents: low relapse rate after treatment according to non-Hodgkin-lymphoma Berlin-Frankfurt-Munster protocols for systemic lymphoma. Haematologica. 2014;99:e238–41.CrossRefGoogle Scholar
  14. 14.
    Yoon JH, Kang HJ, Kim H, et al. Successful treatment of primary central nervous system lymphoma without irradiation in children: single center experience. J Korean Med Sci. 2012;27:1378–84.CrossRefGoogle Scholar
  15. 15.
    Miles R, Raphael M, McCarthy K, et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) International Study Group. Pediatr Blood Cancer. 2008;51:369–74.CrossRefGoogle Scholar
  16. 16.
    Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266–72.CrossRefGoogle Scholar
  17. 17.
    Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24(36):5711–5.CrossRefGoogle Scholar
  18. 18.
    Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034–43.CrossRefGoogle Scholar
  19. 19.
    Barajas RF Jr, Rubenstein JL, Chang JS, Hwang J, Cha S. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol. 2010;31(1):60–6.CrossRefGoogle Scholar
  20. 20.
    Bellinzona M, Roser F, Ostertag H, Gaab RM, Saini M. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol. 2005;31(1):100–5.CrossRefGoogle Scholar
  21. 21.
    Weller M, Martus P, Roth P, Thiel E, Korfel A, German PCNSL Study Group. Surgery for primary CNS lymphoma? Challenging a paradigm. Neuro-Oncology. 2012;14(12):1481–4.CrossRefGoogle Scholar
  22. 22.
    Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24(8):1281–8.CrossRefGoogle Scholar
  23. 23.
    Mathew BS, Carson KA, Grossman SA. Initial response to glucocorticoids. Cancer. 2006;106(2):383–7.CrossRefGoogle Scholar
  24. 24.
    Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23(1):9–17.CrossRefGoogle Scholar
  25. 25.
    Kai Y, Kuratsu J, Ushio Y. Primary malignant lymphoma of the brain in childhood. Neurol Med Chir. 1998;38:232–7.CrossRefGoogle Scholar
  26. 26.
    Mead GM, Bleehen NM, Gregor A, Bullimore J, Shirley D, Rampling RP, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer. 2000;89(6):1359–70.CrossRefGoogle Scholar
  27. 27.
    O’Brien P, Roos D, Pratt G, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol. 2000;18:519–26.CrossRefGoogle Scholar
  28. 28.
    Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036–47.CrossRefGoogle Scholar
  29. 29.
    Said JA, Waters BG, Cousens P, Stevens MM. Neuropsychological sequelae of central nervous system prophylaxis in survivors of childhood acute lymphoblastic leukemia. J Consult Clin Psychol. 1989;57:251–6.CrossRefGoogle Scholar
  30. 30.
    Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol. 1996;14:556–64.CrossRefGoogle Scholar
  31. 31.
    Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer. 2004;90(2):353–8.CrossRefGoogle Scholar
  32. 32.
    Batchelor T, Carson K, O’Neill A, Grossman SA, Alavi J, New P, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21(6):1044–9.CrossRefGoogle Scholar
  33. 33.
    Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31(25):3061–8.CrossRefGoogle Scholar
  34. 34.
    Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31(31):3971–9.CrossRefGoogle Scholar
  35. 35.
    Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217–27.CrossRefGoogle Scholar
  36. 36.
    Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374:1512–20.CrossRefGoogle Scholar
  37. 37.
    Abla O, Branson H, Hawkins C, Weitzman S. Rapid early response to high-dose methotrexate in an adolescent with multifocal primary CNS lymphoma. 12th international conference on malignant lymphoma – Lugano, Switzerland, June 18–21, 2013.Google Scholar
  38. 38.
    O’Suoji C, Welch JJ, Perkins SL, et al. Rare pediatric non-Hodgkin lymphomas: a report from Children’s oncology group study ANHL 04B1. Pediatr Blood Cancer. 2016;63:794–800.CrossRefGoogle Scholar
  39. 39.
    Khan RB, Shi W, Thaler HT, DeAngelis LM, Abrey LE. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neuro-Oncol. 2002;58(2):175–8.CrossRefGoogle Scholar
  40. 40.
    Sierra Del Rio M, Ricard D, Houillier C, Navarro S, Gonzalez-Aguilar A, Idbaih A, et al. Prophylactic intrathecal chemotherapy in primary CNS lymphoma. J Neuro-Oncol. 2012;106(1):143–6.CrossRefGoogle Scholar
  41. 41.
    Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76(10):929–30.CrossRefGoogle Scholar
  42. 42.
    Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83(3):235–9.CrossRefGoogle Scholar
  43. 43.
    Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of Rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. J Clin Oncol. 2016;34. Abstract 10507.CrossRefGoogle Scholar
  44. 44.
    Illerhaus G, Fritsch K, Egerer G, et al. Sequential high dose immuno-chemotherapy followed by autologous peripheral blood stem cell transplantation for patients wtih untreated primary central nervous system lymphoma – a Multicentre Study by the Collaborative PCNSL Study Group Freiburg. Blood 2012, 120. Presented at the American Society of Hematology annual meeting, Atlanta, 2012.Google Scholar
  45. 45.
    Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4(11):e510–23.CrossRefGoogle Scholar
  46. 46.
    Rubenstein JL, Formaker P, Wang X, et al. Lenalidomide is highly active in recurrent CNS lymphomas: phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide as maintenance monotherapy. Hematol Oncol. 2015;33:175. (Abstr 137).Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Oussama Abla
    • 1
    Email author
  • Tracy T. Batchelor
    • 2
  • Andishe Attarbaschi
    • 3
    • 4
  1. 1.Department of Pediatrics, Division of Hematology/OncologyThe Hospital for Sick Children, University of TorontoTorontoCanada
  2. 2.Stephen E. and Catherine Pappas Center for Neuro-OncologyMassachusetts General Hospital Cancer CenterBostonUSA
  3. 3.Department of Pediatric Hematology and OncologySt. Anna Children’s HospitalViennaAustria
  4. 4.Department of Pediatrics and Adolescent MedicineMedical University of ViennaViennaAustria

Personalised recommendations